3Ginsberg JS,Hirsh J. Use of antithrombotic agents during pregnancy [J]. Chest, 1995,108 (4) : 305 - 311.
4Greaves M, Cohen H, MacHin SJ, et al. Guidelines on the investigation and management of the antiphospholipid syndrome [ J ]. Br J Haematol, 2000, 109(4) :704 - 715.
5Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: american college of chest physicians evidence-based clinical practice guidelines (8th edition)[J]. Chest, 2008,133 (6) : 844 - 886.
6Sucak G T,Acar K,Sucak A,et al.Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia[J].Blood Coagul Fibrinolysis,2006,17(5):347-352.
7Chaiworapongsa T,Yoshimatsu J,Espinoza J,et al.Evidence of in vivo generation of thrombin in patients with small-for-gestational-age fetuses and pre-eclampsia[J].J Matern Fetal Neonatal Med,2002,11(6):362-367.
8Roes E M,Sweep C G,Thomas C M,et al.Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia[J].Am J Obstet Gynecol,2002,187(4):1019-1025.
9Belo L,Santos S A,Rumley A,et al.Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia:correlation with proteinuria[J].BJOG,2002,109(11):1250-1255.
10Sucak G T,Acar K,Sucak A,et al.Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia[J].Blood Coagul Fibrinolysis,2006,17(5):347-352.
1Wang L, Brown JR, Varki Aet al. Heparin's anti -inflamma- tory effects require glueosamine sulfation and are mediated by blockade of L and P seleetins [J] . J Clin Invest, 2002, 110 (1): 127.
